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Serotonin (5-hydroxytryptamine, or 5-HT) receptors mediate a plethora of physiological phenomena in the brain 
and the periphery. Additionally, serotonergic dysfunction has been implicated in nearly every neuropsychiatric 
disorder. The effects of serotonin are mediated by fourteen GPCRs. Both the therapeutic actions and side effects of 
commonly prescribed drugs are frequently due to nonspecific actions on various 5-HT receptor subtypes. For more 
than 20 years, the search for clinically efficacious drugs that selectively target 5-HT receptor subtypes has been only 
occasionally successful. This review provides an overview of 5-HT receptor pharmacology and discusses two recent 
5-HT receptor subtype–selective drugs, lorcaserin and pimavanserin, which target the 5HT2C and 5HT2A receptors 
and provide new treatments for obesity and Parkinson’s disease psychosis, respectively.
Serotonin receptors and signal transduction
Serotonin, which was known to be the principal vasoconstricting 
substance found in serum, was chemically identified as 5-hydroxy-
tryptamine by Rapport and colleagues in 1948 (1). Although the 
effects of serotonin on smooth muscle and other peripheral organs 
were long appreciated, it wasn’t until its structural similarity to 
lysergic acid diethylamide (LSD) was noted that serotonin and its 
receptors were linked to neurotransmission (2). Distinct seroto-
nin receptor subtypes were proposed in 1957 (3), with the 5-HT1 
receptors having high affinity for serotonin and the 5-HT2 recep-
tors having relatively low affinity for 5-HT. The so-called 5-HT1 
and 5-HT2 receptors identified pharmacologically by Gaddum 
and colleagues (3) roughly correspond to what are now known as 
the 5-HT1 and 5-HT2 families of receptors (Figure 1). 
With the development of radioligand-binding technology, mul-
tiple distinct serotonin receptors were identified based principally 
on their differential radioligand-binding properties. Following the 
cloning of the β-adrenergic receptor (4), 5-HT1A (5), the first so-
called orphan GPCR, was cloned by Brian Kobilka in collaboration 
with Marc Caron and others (6, 7). In rapid succession, the large 
family of G protein–coupled serotonin receptors we now appreci-
ate were identified by molecular cloning technology and charac-
terized by pharmacological and biochemical studies (8, 9), includ-
ing 5-HT1B/1D (10) and 5-HT1E (11), as well as 5-HT2A (12, 13) and 
5-HT2C (14, 15), which have lower affinities for 5-HT than the other 
serotonin receptors. The 5-HT4 receptor was also one of the early 
5-HT receptor subtypes identified mainly by radioligand binding 
and pharmacological studies (refs. 16, 17, and see Figure 1).
In terms of signal transduction and pharmacology, we now 
know that all members of the 5-HT1 family are intronless and 
couple to the Gi family of heterotrimeric G proteins — in keep-
ing with the original description of the 5-HT1A receptor (7). The 
5-HT1 family of receptors has been successfully exploited for the 
treatment of anxiety and depression with the development of 
drugs like buspirone (Table 1), which is a selective 5-HT1A partial 
agonist. Likewise, 5-HT1B and 5-HT1D receptors represent canoni-
cal targets for antimigraine medications including various ergots 
(e.g., ergotamine, dihydroergotamine, and methysergide) as well 
as the more selective tryptans (e.g., sumatryptan and analogs) 
(18, 19). No selective 5-HT1E drugs exist and though selective 
5-HT1F drugs have been developed, none of them have yet been 
approved by the FDA (Table 1). Theoretically, 5-HT1F antagonists 
might represent novel therapeutic agents for migraine headaches.
The 5-HT2 family receptors couple to Gq G proteins and modu-
late phosphoinositide hydrolysis and PKC activation (20–22). 5-HT2 
family receptors typically have lower affinity for molecular seroto-
nin than other 5-HT receptors and are often potently inhibited by 
both typical (12) and atypical (23) antipsychotic drugs (24). 5-HT2A 
receptors represent the main serotonin receptors found in platelets, 
vascular smooth muscle, and the cerebral cortex (25, 26). As dis-
cussed below, 5-HT2B receptors are enriched in the heart (27), and 
drugs likely mediate their valvulopathogenic actions on heart valves 
via a combination of G protein and β-arrestin signaling (27–29). The 
distribution and function of 5-HT2C receptors will be summarized 
below when lorcaserin, a selective 5-HT2C agonist, is discussed.
The 5-HT4, 5-HT6, and 5-HT7 families of receptors are all cou-
pled to the Gs G proteins and mediate the stimulatory effects of 
serotonin on cAMP accumulation. 5-HT4 receptors represent the 
main site of action of many drugs used for treating gastrointesti-
nal motility disorders (Table 1) and are found widely distributed 
throughout the body (18). 5-HT6 and 5-HT7 receptors have recently 
been the subject of intense investigation by pharmaceutical compa-
nies based on the discovery that many atypical antipsychotic drugs 
have high affinities for both receptors (30). As can be seen in Table 1, 
compounds that target 5-HT6 and 5-HT7 receptors are currently 
in testing for depression, cognition enhancement, and psychosis.
Drugs acting on 5-HT receptors display a range of efficacy from full 
agonists to inverse agonists (e.g., antagonists with negative intrin-
sic activity). Buspiron, for instance, is a partial agonist at 5-HT1A 
receptors, whereas sumatriptan is a full agonist at 5-HT1D recep-
tors. By contrast, both typical and atypical antipsychotic drugs have 
inverse agonist actions at many 5-HT receptor subtypes including 
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5-HT2A (31) and 5-HT2C (32). Inverse agonists represent drugs that 
antagonize the action of full agonists (e.g., are “antagonists”) and 
simultaneously lower the basal level of receptor signaling (e.g., sup-
press constitutive receptor activity; see ref. 33 for review). Essen-
tially, inverse agonists are antagonists with negative intrinsic activ-
ity. Finally, drugs like ergotamine display functional selectivity or 
signaling bias for many 5-HT receptors including 5-HT2B (28, 29). 
Thus, ergotamine has much higher potency for activating β-arrestin 
pathways than for activating G protein–mediated signaling (28, 29) 
and as such is considered to display functional selectivity for β-ar-
restin signaling and to represent a β-arrestin–biased agonist.
Because of the vast effort devoted over the past five decades to 
studying serotonin and classifying its receptors, we now appreci-
ate that serotonin is involved in the regulation of nearly every CNS 
function, including cognition, autonomic function, perception, 
emotion, appetite, aggression, and mood, to name but a few (18). 
Additionally, alterations in serotonergic neurotransmission have 
been implicated in nearly every neuropsychiatric disorder, including 
schizophrenia and related psychotic disorders, major depression, 
eating disorders, and so on (18). Many of the therapeutic actions, as 
well as serious side effects of commonly prescribed medications, are 
due to nonspecific actions on 5-HT receptor subtypes (18, 27, 34). 
Given this wealth of evidence implicating altered serotonergic neu-
rotransmission in neuropsychiatric disease, as well as the plethora 
of 5-HT receptor subtypes, it has long been proposed that drugs 
that target distinct 5-HT receptors might provide novel and effective 
treatments for many neuropsychiatric disorders (Table 1).
Despite the abundant evidence suggesting that selective sero-
tonergic drugs would prove efficacious for many diseases, a fun-
damental challenge encountered for creating them relates to the 
relatively similar binding pocket shared among 5-HT receptor sub-
types. As seen in recent high-resolution structures derived from the 
Figure 1
Sites of action of 5-HT therapeutics. Shown in the middle is a table 
listing the major families of 5-HT receptors (viz. 5-HT1 to 5-HT7). As 
shown, the 5-HT1 family has five members (5-HT1A, 5-HT1B, 5-HT1D, 
5-HT1E, and 5-HT1F), while the 5-HT2 family — the topic of this review 
— has three: 5-HT2A, 5-HT2B, and 5-HT2C. Each member of the 5-HT2 
family displays distinct brain and tissue distributions. The 5-HT2A recep-
tor is enriched in pyramidal neurons in layer V of the cerebral cortex, 
where it mediates the actions of pimavanserin and other atypical anti-
psychotic drugs. The 5-HT2B receptor is enriched in interstitial cells of 
the heart valves, where it mediates the valvulopathic actions of certain 
drugs like fenfluramine. The 5-HT2C receptor is enriched in the hypo-
thalamus, among other areas, particularly in nuclei engaged in regu-
lating feeding behavior, where it mediates the actions of the appetite 
suppressant lorcaserin.
Table 1
Listed are approved/investigational drugs targeting distinct 5-HT receptor subtypes
Receptor subtype Known indications (medication name) Potential new indications (medication name) References
5-HT1A Anxiety, depression Cognition enhancement 77 
 (buspirone) (tandospirone)
5-HT1B Migraine headaches Depression (AZD3783) 78 
  and 5-HT1D (sumatriptan, rizatriptan, zolmitriptan, etc.)
5-HT1E Unknown NA 
5-HT1F Migraine headaches NA 
5-HT2A Hypertension (ketanserin) Psychosis (pimavanserin) This article
5-HT2B Pulmonary hypertension Fibrosis (NA)  
 (terguride)
5-HT2C Obesity (lorcaserin) Psychosis, mood disorders,  18 
  anxiety, metabolic syndrome
5-HT3 Chemotherapy-induced nausea NA  
 (odansetron, granisetron,tropisetron, etc.)
5-HT4 Gastrointestinal motility disorders Dementia (NA) 79 
 (metoclopramide)
5-HT5 Unknown NA 
5-HT6 NA Cognition enhancement in 80 
  Alzheimer’s disease, psychosis (SB-742457)
5-HT7 NA Depression, anxiety (NA) 81
 
review
4988 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 12   December 2013
pharmacologically distinct 5-HT1B and 5-HT2B receptors (refs. 19, 
29, and Figure 2), many of the key amino acids essential for ligand 
binding by the G protein–coupled 5-HT receptors are identical. 
Until recently, this high degree of structural conservation made 
it challenging for medicinal chemists to create subtype-selective 
5-HT receptor–active drugs. As is evident from Table 1, and as has 
been briefly reviewed earlier, several selective serotonergic drugs 
have now survived the gauntlet of clinical trials and are approved 
for treating a number of diseases, including obesity, migraine 
headaches, psychosis, anxiety, depression, chemotherapy-induced 
nausea, and even Alzheimer’s disease.
In this review, we focus on one newly approved 5-HT2C–selective 
antiobesity medication (lorcaserin) and a 5-HT2A–selective inverse 
agonist with efficacy in the dopamine-dependent psychosis of Par-
kinson’s disease (pimavanserin) that has recently been selected for 
expedited FDA review (see Figure 2 for structures). Currently, there 
is no approved treatment for this relatively common disorder. 
Clozapine and quetiapine, which are nonselective inverse agonists 
at the 5-HT2A receptor are rarely used because of unwanted side 
effects caused by their actions at other receptors (35).
Lorcaserin — a safe and effective antiobesity drug
For many decades, it has been clear that 5-HT is a critically impor-
tant neurotransmitter for the central regulation of appetite and 
metabolism (36) and that it is the 5-HT2C receptor that mediates 
the anorectic actions of 5-HT (37). The anorectic actions of the 
withdrawn antiobesity medication fenfluramine are due to the 
agonist actions of its metabolite norfenfluramine at 5-HT2C recep-
tors (38). The combination of fenfluramine and the amphetamine 
derivative phentermine was demonstrated to be a highly effective 
appetite suppressant (39), but was withdrawn due an unacceptable 
rate of valvular heart disease (40). Fenfluramine was also linked 
to pulmonary hypertension, although the incidence was consider-
ably lower than that of valvular heart disease (41). We now know 
that both valvular heart disease (42) and pulmonary hypertension 
(43) are likely due to off-target interactions of fenfluramine’s 
principal metabolite norfenfluramine with the 5-HT2B serotonin 
receptor (27). Thus, while the parent compound fenfluramine 
is relatively inactive at 5-HT2B receptors (42), norfenfluramine 
potently activates 5-HT2B receptors (42, 44). Indeed, the EC50 of 
norfenfluramine is approximately 80 nM for the activation of 
5-HT2B receptors in vitro. This concentration is roughly equivalent 
to plasma levels of norfenfluramine in individuals taking fenflu-
ramine for obesity (18). Thus, Arena Pharmaceuticals set out to 
create a 5-HT2C–selective agonist devoid of 5-HT2B agonist activity, 
predicting that such a molecule would be an effective anorectic 
agent devoid of cardiovascular side effects. Lorcaserin (also known 
as APD356) (Figure 2B and ref. 45) satisfied these criteria and was 
entered into clinical trials for the treatment of obesity.
In 2010, the results from a large phase III clinical trial were 
published (46), demonstrating that lorcaserin-treated indi-
viduals (10 mg/day) achieved, on average, a 5.8-kg weight loss 
compared with a 2.2-kg weight loss in placebo-treated patients 
(P < 0.001) (Figure 3A). Both lorcaserin- and placebo-treated 
individuals were given diet and exercise guidance, with 47.5% 
of lorcaserin-treated patients achieving ≥5% weight loss com-
pared with 20.3% for those treated with placebo (Figure 3B). 
Importantly, there was no evidence for an increase in clinically 
significant valvular heart disease in lorcaserin-treated patients 
compared with those receiving placebo. Similar results were 
reported in a 1-year trial that examined two doses of lorcaserin 
(10 or 20 mg/day); again, there was no difference in the inci-
dence of valvular heart disease in placebo- and lorcaserin-treated 
individuals (2.0% in both). In both trials, headache, nausea, and 
dizziness were among the most frequent side effects, and there 
was no evidence for neuropsychiatric sequelae in either trial 
(46, 47). Nasopharyngitis, sinusitis, and upper respiratory infec-
tions were seen more commonly among lorcaserin-treated indi-
viduals in one trial (46), but not in the other (47). Lorcaserin 
appears to achieve its weight-reducing effects by diminishing 
caloric intake rather than by altering energy expenditure (48).
Figure 2
Structures of lorcaserin and pimavanserin in relationship to the sero-
tonin receptor–binding pocket. Shown at the top are the structures of 
lorcaserin ((1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benza-
zepine) and pimavanserin (N-(4-fluorophenylmethyl)-N-(1-methylpip-
eridin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide), and 
shown below is the consensus-binding pocket of 5-HT receptors.
Figure 3
Lorcaserin induces significant weight loss. (A) Average weight loss 
versus placebo with lorcaserin treatment (n = 1,538 in lorcaserin group 
vs. 1,499 in placebo group; P < 0.001). (B) Percentage of patients in 
each group who achieved ≥5% weight loss (P < 0.001 lorcaserin vs. 
placebo). Data republished with permission from ref. 46.
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Lorcaserin has also been evaluated in obese individuals with type 2 
diabetes. In a pivotal study, O’Neill et al. found that lorcaserin 
induced significant (P < 0.001) weight loss and improved glyce-
mic control in individuals with type 2 diabetes compared with 
that observed in placebo-treated individuals (49). It must be noted 
that both groups received metformin or sulfonylurea (or both), as 
well as diet and exercise counseling. Thus, it cannot be concluded 
without further study that lorcaserin alone would be effective in 
producing weight loss in obese individuals with type 2 diabetes. As 
in all other studies, serial echocardiograms were performed, and 
no significant (P > 0.05) drug effect was noted on the incidence of 
valvular heart disease. Taken together, these results suggest that 
lorcaserin in combination with diet and exercise counseling can 
induce clinically significant weight loss and, perhaps, improve gly-
cemic control in obese individuals with type 2 diabetes.
Treating Parkinson’s disease psychosis: from clozapine 
to pimavanserin
It has long been held that all antipsychotic drugs (APDs) achieve 
their antipsychotic effect primarily through blockade of dopamine 
(DA) D2 receptors (50); however, D2 receptor blockade also leads to 
deleterious extrapyramidal side effects (EPSs) and prolactin eleva-
tion (51). At doses of 200 to 900 mg/day, clozapine was found to 
produce antipsychotic action with minimal EPSs or prolactin ele-
vation in patients with schizophrenia, an atypical profile compared 
with other APDs (52, 53). Comparison of the affinities of typical 
and atypical APDs for DA D1 and D2 and 5-HT2A receptors led to 
the hypothesis that one type of atypical APD could be identified by 
a higher affinity for 5-HT2A receptors than for D2 receptors (54). 
Subsequently, a series of drugs that conformed to this hypothesis, 
including risperidone, olanzapine, and others, were developed for 
the treatment of schizophrenia (55). Unfortunately, other pharma-
cologic properties of these broadly acting drugs produced numer-
ous side effects that limited their tolerability (56), including 5-HT2C 
inverse agonism, a major basis for metabolic side effects (57).
Typical APDs, even at ultra-low doses, cause intolerable motor 
impairment in patients with Parkinson’s disease psychosis (PDP), 
which is a common side effect of L-DOPA and direct-acting DA 
agonists. By contrast, clozapine, at doses of 12.5 to 75 mg/day, was 
found to be an effective and tolerable treatment for PDP (35); how-
ever, serious, nonmotoric side effects of clozapine limit its use in 
PDP (30, 35). After an examination of plasma levels of clozapine 
(4–6 ng/ml) in responsive PDP patients, it was concluded that clo-
zapine’s antagonist (or inverse agonist) activity at 5-HT2A receptors 
was the basis for its efficacy (58). This provided further support 
for the suggestion that selective 5-HT2A inverse agonists might be 
useful as a monotherapy for some psychoses and to potentiate the 
antipsychotic action of subeffective doses of known APDs (24, 59). 
For these and other reasons, ACADIA Pharmaceuticals developed 
selective 5-HT2A inverse agonists (31, 35). The compound ulti-
mately selected for clinical development was pimavanserin (60). Its 
pKi (–log Ki) for the human 5-HT2A receptor is 9.3, with a 40-fold 
selectivity over the 5-HT2C receptors and little affinity for 5-HT2B 
or D2 receptors (60). Pimavanserin demonstrated atypical antipsy-
chotic-like activity in a variety of preclinical models (37, 38, 60). 
It also reduced the release of DA in the nucleus accumbens from 
activated DA neurons (61), which may contribute to its antipsy-
chotic effect, although direct effects on 5-HT2A receptors expressed 
on glutamatergic and GABAergic neurons may also contribute to 
the actions of 5-HT2A inverse agonists (55, 62).
Pimavanserin, 20–60 mg/day, was tested in a double-blind, 
randomized, placebo-controlled, multicenter 28-day trial in 
60 patients with L-DOPA–induced PDP (63). The pimavanser-
in-treated patients showed markedly greater improvement in delu-
sions and hallucinations (Figure 4). Pimavanserin did not differen-
tiate from the placebo with regard to motor impairment, sedation, 
hypotension, or other side effects (39, 63). These results were 
recently confirmed in a 6-week, randomized, double-blind phase 
III study involving 198 patients, half of whom received pimavan-
serin (64). The FDA subsequently indicated that it will evaluate a 
new drug application (NDA) from ACADIA on the basis of these 
two studies and other safety data (65). Preclinical studies indicate 
that pimavanserin may also be useful for treating the psychosis 
of Alzheimer’s disease (66). Pimavanserin has also been shown to 
potentiate a subeffective dose of the atypical APD risperidone in 
acutely psychotic patients with schizophrenia, producing a more 
rapid onset of action than standard-dose risperidone or an equally 
effective dose of haloperidol, while producing fewer side effects 
(67). These results are consistent with evidence that pimavan-
serin, as well as other 5-HT2A inverse agonists, is able to potentiate 
subeffective doses of atypical, but not typical, APDs in clinically 
relevant animal models of psychosis and cognitive impairment 
(68, 69). The possibility that pimavanserin is effective as a mono-
therapy for some patients with schizophrenia is consistent with 
Figure 4
Pimavanserin significantly improves delusions and hallucinations in 
PDP. Baseline and 28-day scale for the assessment of positive symp-
toms (SAPS) of global delusions (A) and hallucinations (B) ratings for 
30 patients per group with PDP treated with pimavanserin or placebo 
(P < 0.05), respectively. Data republished with permission from ref. 63.
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the finding that SR43469B, another 5-HT2A inverse agonist, was 
reported to diminish psychotic symptoms more effectively than 
placebo, but slightly less so than haloperidol, in acutely psychotic 
patients with schizophrenia (59).
Conclusions
The approval of lorcaserin by the FDA in June 2012 marks the cul-
mination of many years of basic science investigation in fields as 
disparate as the central control of appetite and drug-induced val-
vular heart disease. Thus, the pivotal discoveries that 5-HT2C recep-
tors are essential mediators of both appetite (37) and the anorectic 
actions of fenfluramine (38) and that the closely related receptor 
5-HT2B is responsible for drug-induced valvular heart disease 
(27, 42) paved the way for the design of novel serotonergic drugs 
predicted to be effective in reducing appetite without cardiovas-
cular side effects. Additionally, since it is now well established that 
drugs can selectively engage either G protein or β-arrestin signal-
ing (70, 71), drugs with selective signaling bias for one pathway 
over another may have distinct clinical advantages over drugs 
without functional selectivity (72–75). It will be important to 
determine whether 5-HT2C agonists with signaling bias represent 
a therapeutic advance over drugs without functional selectivity.
The clinical studies cited here (58) are consistent with preclini-
cal data demonstrating that selective 5-HT2A inverse agonism is a 
valuable mechanism for treating psychosis with fewer side effects, 
both as monotherapy and adjunctive treatment. One thing that 
is unclear, however, is the degree of inverse agonism required for 
therapeutic efficacy in psychosis and related disorders (76), and 
future studies examining drugs with a range of antagonist func-
tional selectivity and inverse agonism will be needed to address 
this point. Finally, additional extensive research is needed to estab-
lish the range of disorders in which 5-HT2A inverse agonists can 
substitute for or augment subeffective doses of APDs. At least for 
PDP, pimavanserin may be considered a potential next-generation 
atypical APD.
Taken together, these findings underscore the importance of 
an in-depth understanding of the biology and pharmacology of 
specific subtypes of 5-HT receptors and how this may lead to the 
development of novel treatments with selective clinical efficacies 
and fewer side effects compared with prior medications.
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